Michael Choi

Title(s)Associate Clinical Professor, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Overview 

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mutation in Bruton Tyrosine Kinase (BTK) A428D confers resistance To BTK-degrader therapy in chronic lymphocytic leukemia. Leukemia. 2024 Aug; 38(8):1818-1821. Wong RL, Choi MY, Wang HY, Kipps TJ. PMID: 39048721; PMCID: PMC11286506.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    2. Aberrant spliceosome activity via elevated intron retention and upregulation and phosphorylation of SF3B1 in chronic lymphocytic leukemia. Mol Ther Nucleic Acids. 2024 Jun 11; 35(2):102202. Kashyap MK, Karathia H, Kumar D, Vera Alvarez R, Forero-Forero JV, Moreno E, Lujan JV, Amaya-Chanaga CI, Vidal NM, Yu Z, Ghia EM, Lengerke-Diaz PA, Achinko D, Choi MY, Rassenti LZ, Mariño-Ramírez L, Mount SM, Hannenhalli S, Kipps TJ, Castro JE. PMID: 38846999; PMCID: PMC11154714.
      View in: PubMed   Mentions:
    3. A + AVD for Treatment of Hodgkin Lymphoma Variant of Richter's Transformation. Case Rep Hematol. 2024; 2024:7612622. Heyman B, Choi M, Kipps TJ. PMID: 38434151; PMCID: PMC10908572.
      View in: PubMed   Mentions:
    4. Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells. J Immunother Cancer. 2024 02 05; 12(2). Botta GP, Chao J, Ma H, Hahn M, Sierra G, Jia J, Hendrix AY, Nolte Fong JV, Ween A, Vu P, Miller A, Choi M, Heyman B, Daniels GA, Kaufman D, Jamieson C, Li Z, Cohen E. PMID: 38316518; PMCID: PMC10860094.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    5. Novel BRAF N581S mutation in mantle cell lymphoma. EJHaem. 2024 Feb; 5(1):247-250. Hariharan N, Bedi D, Choi MY, Wang HY, Heyman BM. PMID: 38406519; PMCID: PMC10887227.
      View in: PubMed   Mentions: 1  
    6. Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv. 2023 09 26; 7(18):5294-5303. Moreno C, Solman IG, Tam CS, Grigg A, Scarfò L, Kipps TJ, Srinivasan S, Mali RS, Zhou C, Dean JP, Szafer-Glusman E, Choi M. PMID: 37315225; PMCID: PMC10506056.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    7. Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach. Cancers (Basel). 2023 Sep 08; 15(18). Chen CJ, Choi MY, Heyman BM. PMID: 37760453; PMCID: PMC10526830.
      View in: PubMed   Mentions: 2  
    8. Obinutuzumab, High-Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients with Richter's Syndrome. Cancers (Basel). 2022 Dec 08; 14(24). Heyman BM, Choi MY, Kipps TJ. PMID: 36551520; PMCID: PMC9775482.
      View in: PubMed   Mentions: 5  
    9. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen. Blood Adv. 2022 08 09; 6(15):4553-4557. Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovic M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. PMID: 35736670; PMCID: PMC9636322.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    10. Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke. Clin Lymphoma Myeloma Leuk. 2022 11; 22(11):e959-e971. Narezkina A, Akhter N, Lu X, Emond B, Panjabi S, Forbes SP, Hilts A, Liu S, Lafeuille MH, Lefebvre P, Huang Q, Choi M. PMID: 35973891.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    11. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia. Leukemia. 2022 06; 36(6):1609-1618. Ghia EM, Rassenti LZ, Choi MY, Quijada-Álamo M, Chu E, Widhopf GF, Kipps TJ. PMID: 35418613; PMCID: PMC9162914.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    12. Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica. 2022 04 01; 107(4):984-987. Allan JN, Pinilla-Ibarz J, Gladstone DE, Patel K, Sharman JP, Wierda WG, Choi MY, O'Brien SM, Shadman M, Davids MS, Pagel JM, Yimer HA, Ward R, Acton G, Taverna P, Combs DL, Fox JA, Furman RR, Brown JR. PMID: 34937320; PMCID: PMC8968902.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    13. Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576. Adv Hematol. 2022; 2022:4450824. Castro JE, Lengerke-Diaz PA, Velez Lujan J, Choi MY, Moreno-Cortes EF, Forero JV, Garcia-Robledo JE, Jacobs C, McCarthy C, Heinen A, Amaya-Chanaga CI, Kipps TJ. PMID: 35103064; PMCID: PMC8800600.
      View in: PubMed   Mentions: 2  
    14. Improving the outlook for TP53-aberrant CLL. Blood. 2021 11 11; 138(19):1785-1786. Choi MY. PMID: 34762129; PMCID: PMC9642792.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers. NEJM Evid. 2022 01; 1(1):EVIDoa2100001. Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, de Vos S, Kallam A, Patel K, Kipps TJ, Rule S, Flanders K, Jessen KA, Ren H, Riebling PC, Graham P, King L, Thurston AW, Sun M, Schmidt EM, Lannutti BJ, Johnson DM, Miller LL, Spurgeon SE. PMID: 38319241.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    16. Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 2021 09 09; 138(10):836-846. Ma S, Seymour JF, Brander DM, Kipps TJ, Choi MY, Anderson MA, Humphrey K, Al Masud A, Pesko J, Nandam R, Salem AH, Chyla B, Arzt J, Jacobson A, Kim SY, Roberts AW. PMID: 34115103; PMCID: PMC9710452.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    17. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy. Clin Cancer Res. 2020 07 15; 26(14):3589-3596. Mato AR, Roeker LE, Jacobs R, Hill BT, Lamanna N, Brander D, Shadman M, Ujjani CS, Yazdy MS, Perini GF, Pinilla-Ibarz JA, Barrientos J, Skarbnik AP, Torka P, Pu JJ, Pagel JM, Gohil S, Fakhri B, Choi M, Coombs CC, Rhodes J, Barr PM, Portell CA, Parry H, Garcia CA, Whitaker KJ, Winter AM, Sitlinger A, Khajavian S, Grajales-Cruz AF, Isaac KM, Shah P, Akhtar OS, Pocock R, Lam K, Voorhees TJ, Schuster SJ, Rodgers TD, Fox CP, Martinez-Calle N, Munir T, Bhavsar EB, Bailey N, Lee JC, Weissbrot HB, Nabhan C, Goodfriend JM, King AC, Zelenetz AD, Dorsey C, Bigelow K, Cheson BD, Allan JN, Eyre TA. PMID: 32198151; PMCID: PMC8588795.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    18. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study. Leuk Res. 2020 02; 89:106302. Gordon MJ, Sitlinger A, Salous T, Alqahtani H, Churnetski M, Rivera X, Wisniewski P, Cohen J, Patel K, Shadman M, Choi M, Hill B, Stephens D, Persky D, Brander D, Danilov AV. PMID: 31982152.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Targeted Therapy in Chronic Lymphocytic Leukemia. Cancer J. 2019 Nov/Dec; 25(6):378-385. Kipps TJ, Choi MY. PMID: 31764118; PMCID: PMC7039327.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    20. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia. Blood. 2019 09 26; 134(13):1084-1094. Chen Y, Chen L, Yu J, Ghia EM, Choi MY, Zhang L, Zhang S, Sanchez-Lopez E, Widhopf GF, Messer K, Rassenti LZ, Jamieson C, Kipps TJ. PMID: 31409670; PMCID: PMC6764264.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    21. SOHO State of the Art Updates and Next Questions: The Conundrum in Assessing the Therapy Response of Patients With Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):321-325. Choi MY, Wang HY, Kipps TJ. PMID: 31204237.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020 01; 105(1):e22-e25. Lujan JV, Lengerke-Diaz PA, Jacobs C, Moreno-Cortes EF, Ramirez-Segura CA, Choi MY, McCarthy C, Heinen A, Kipps TJ, Castro JE. PMID: 31048356; PMCID: PMC6939526.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    23. Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy. Haematologica. 2019 11; 104(11):2258-2264. Mato AR, Wierda WG, Davids MS, Cheson BD, Coutre SE, Choi M, Furman RR, Heffner L, Barr PM, Eradat H, Ford SM, Zhou L, Verdugo M, Humerickhouse RA, Potluri J, Byrd JC. PMID: 30923097; PMCID: PMC6821597.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCellsCTClinical Trials
    24. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials. Cancers (Basel). 2018 Dec 21; 11(1). Galanina N, Bejar R, Choi M, Goodman A, Wieduwilt M, Mulroney C, Kim L, Yeerna H, Tamayo P, Vergilio JA, Mughal TI, Miller V, Jamieson C, Kurzrock R. PMID: 30583461; PMCID: PMC6356731.
      View in: PubMed   Mentions: 16  
    25. Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B-cell receptor pathway inhibitor. Br J Haematol. 2019 06; 185(5):961-966. Wierda WG, Byrd JC, Davids MS, Furman RR, Cheson BD, Barr PM, Eradat H, Heffner L, Zhou L, Verdugo M, Potluri J, Choi M. PMID: 30478940; PMCID: PMC6587980.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    26. JAK2 V617F mutation in plasma cell-free DNA preceding clinically overt myelofibrosis: Implications for early diagnosis. Cancer Biol Ther. 2018 08 03; 19(8):664-668. Choi MY, Kato S, Wang HY, Lin JH, Lanman RB, Kurzrock R. PMID: 29565699; PMCID: PMC6067874.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia. Cell Stem Cell. 2018 Jun 01; 22(6):951-959.e3. Choi MY, Widhopf GF, Ghia EM, Kidwell RL, Hasan MK, Yu J, Rassenti LZ, Chen L, Chen Y, Pittman E, Pu M, Messer K, Prussak CE, Castro JE, Jamieson C, Kipps TJ. PMID: 29859176; PMCID: PMC7001723.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    28. Comorbidities predict inferior outcomes in chronic lymphocytic leukemia treated with ibrutinib. Cancer. 2018 08 01; 124(15):3192-3200. Gordon MJ, Churnetski M, Alqahtani H, Rivera X, Kittai A, Amrock SM, James S, Hoff S, Manda S, Spurgeon SE, Choi M, Cohen JB, Persky D, Danilov AV. PMID: 29797667.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    29. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 04 12; 131(15):1704-1711. Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, Chyla B, Zhou L, Agarwal S, Waskiewicz T, Verdugo M, Humerickhouse RA, Potluri J, Wierda WG, Davids MS. PMID: 29305552; PMCID: PMC5922273.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCTClinical Trials
    30. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 01; 19(1):65-75. Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. PMID: 29246803; PMCID: PMC6027999.
      View in: PubMed   Mentions: 163     Fields:    Translation:HumansCTClinical Trials
    31. BRAF mutation as a novel driver of eosinophilic cystitis. Cancer Biol Ther. 2017 Sep 02; 18(9):655-659. Choi MY, Tsigelny IF, Boichard A, Skjevik ÅA, Shabaik A, Kurzrock R. PMID: 28829677; PMCID: PMC5663411.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    32. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J Hematol Oncol. 2017 05 19; 10(1):112. Kashyap MK, Amaya-Chanaga CI, Kumar D, Simmons B, Huser N, Gu Y, Hallin M, Lindquist K, Yafawi R, Choi MY, Amine AA, Rassenti LZ, Zhang C, Liu SH, Smeal T, Fantin VR, Kipps TJ, Pernasetti F, Castro JE. PMID: 28526063; PMCID: PMC5438492.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    33. Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies. JCO Precis Oncol. 2017 06; 1. Goodman AM, Choi M, Wieduwilt M, Mulroney C, Costello C, Frampton G, Miller V, Kurzrock R. PMID: 28681041; PMCID: PMC5495179.
      View in: PubMed   Mentions: 15     Fields:    
    34. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017 Feb; 18(2):230-240. Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, Anderson MA, Beaven AW, Rosen ST, Tam CS, Prine B, Agarwal SK, Munasinghe W, Zhu M, Lash LL, Desai M, Cerri E, Verdugo M, Kim SY, Humerickhouse RA, Gordon GB, Kipps TJ, Roberts AW. PMID: 28089635; PMCID: PMC5316338.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCTClinical Trials
    35. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort. Oncotarget. 2016 Nov 15; 7(46):75729-75738. Johnson J, Choi M, Dadmanesh F, Han B, Qu Y, Yu-Rice Y, Zhang X, Bagaria S, Taylor C, Giuliano AE, Amersi F, Cui X. PMID: 27708239; PMCID: PMC5342773.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    36. How Do Targeted Therapies Change the Management of Indolent Lymphomas? Oncology (Williston Park). 2016 09 15; 30(9):859-60. Choi MY, Kipps TJ. PMID: 27633418.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    37. An 84-Year-Old Woman With an Indolent B-Cell Lymphoma. Oncology (Williston Park). 2016 08 15; 30(8):705-8, 710, 712. Goodman AM, Choi M, Wang L, Kurzrock R. PMID: 27535668.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    38. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor. Best Pract Res Clin Haematol. 2016 03; 29(1):40-53. Choi MY, Kashyap MK, Kumar D. PMID: 27742071.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    39. ATM Mutations in Cancer: Therapeutic Implications. Mol Cancer Ther. 2016 08; 15(8):1781-91. Choi M, Kipps T, Kurzrock R. PMID: 27413114.
      View in: PubMed   Mentions: 234     Fields:    Translation:HumansAnimals
    40. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19; 7(3):2809-22. Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE. PMID: 26646452; PMCID: PMC4823073.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCells
    41. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15 Suppl:S167-9. Choi MY, Widhopf GF, Wu CC, Cui B, Lao F, Sadarangani A, Cavagnaro J, Prussak C, Carson DA, Jamieson C, Kipps TJ. PMID: 26297272; PMCID: PMC4548279.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    42. AGS67E, an Anti-CD37 Monomethyl Auristatin E Antibody-Drug Conjugate as a Potential Therapeutic for B/T-Cell Malignancies and AML: A New Role for CD37 in AML. Mol Cancer Ther. 2015 Jul; 14(7):1650-60. Pereira DS, Guevara CI, Jin L, Mbong N, Verlinsky A, Hsu SJ, Aviña H, Karki S, Abad JD, Yang P, Moon SJ, Malik F, Choi MY, An Z, Morrison K, Challita-Eid PM, Doñate F, Joseph IB, Kipps TJ, Dick JE, Stover DR. PMID: 25934707; PMCID: PMC4557793.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    43. Potent fluorinated agelastatin analogues for chronic lymphocytic leukemia: design, synthesis, and pharmacokinetic studies. J Med Chem. 2014 Jun 26; 57(12):5085-93. Stout EP, Choi MY, Castro JE, Molinski TF. PMID: 24673739; PMCID: PMC4079331.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    44. Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J. 2012 Sep-Oct; 18(5):404-10. Choi MY, Kipps TJ. PMID: 23006944; PMCID: PMC3461329.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    45. Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci U S A. 2011 Aug 09; 108(32):13253-7. Lu D, Choi MY, Yu J, Castro JE, Kipps TJ, Carson DA. PMID: 21788521; PMCID: PMC3156152.
      View in: PubMed   Mentions: 173     Fields:    Translation:HumansCells
    Michael's Networks
    Concepts (193)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (33)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSD Profiles is managed by the UC San Diego Altman Clinical and Translational Research Institute (ACTRI).
    This site is running Profiles RNS version UCSF-v3.1.0-15-g9ae42700 on PROFILES-PWEB04. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California